Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Molecular Cancer
Published in: Molecular Cancer 1/2019

Open Access 01-12-2019 | Pancreatic Cancer | Review

Role of the microbiome in occurrence, development and treatment of pancreatic cancer

Authors: Yicheng Wang, Gang Yang, Lei You, Jinshou Yang, Mengyu Feng, Jiangdong Qiu, Fangyu Zhao, Yueze Liu, Zhe Cao, Lianfang Zheng, Taiping Zhang, Yupei Zhao

Published in: Molecular Cancer | Issue 1/2019

Login to get access

Abstract

Pancreatic cancer is one of the most lethal malignancies. Recent studies indicated that development of pancreatic cancer may be intimately connected with the microbiome. In this review, we discuss the mechanisms through which microbiomes affect the development of pancreatic cancer, including inflammation and immunomodulation. Potential therapeutic and diagnostic applications of microbiomes are also discussed. For example, microbiomes may serve as diagnostic markers for pancreatic cancer, and may also play an important role in determining the efficacies of treatments such as chemo- and immunotherapies. Future studies will provide additional insights into the various roles of microbiomes in pancreatic cancer.
Literature
1.
2.
3.
4.
Pushalkar S, et al. The pancreatic Cancer microbiome promotes Oncogenesis by induction of innate and adaptive immune suppression. Cancer Discov. 2018;8(4):403–16.PubMedPubMedCentralCrossRef
5.
Panebianco C, et al. Influence of gemcitabine chemotherapy on the microbiota of pancreatic cancer xenografted mice. Cancer Chemother Pharmacol. 2018;81(4):773–82.PubMedCrossRef
6.
Armstrong, H., et al., The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It. Cancers (Basel), 2018. 10(3).PubMedCentralCrossRef
7.
8.
9.
Olson SH, et al. The oral microbiota in patients with pancreatic cancer, patients with IPMNs, and controls: a pilot study. Cancer Causes Control. 2017;28(9):959–69.PubMedPubMedCentralCrossRef
10.
11.
Farrell JJ, et al. Variations of oral microbiota are associated with pancreatic diseases including pancreatic cancer. Gut. 2012;61(4):582–8.PubMedCrossRef
12.
Mitsuhashi K, et al. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget. 2015;6(9):7209–20.PubMedPubMedCentralCrossRef
13.
14.
Memba R, et al. The potential role of gut microbiota in pancreatic disease: a systematic review. Pancreatology. 2017;17(6):867–74.PubMedCrossRef
15.
16.
Jia G, et al. The oral microbiota - a mechanistic role for systemic diseases. Br Dent J. 2018;224(6):447–55.PubMedCrossRef
17.
Cani, P.D. and B.F. Jordan, Gut microbiota-mediated inflammation in obesity: a link with gastrointestinal cancer. Nat Rev Gastroenterol Hepatol, 2018.
18.
Fan X, et al. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study. Gut. 2018;67(1):120–7.PubMedCrossRef
19.
Ogrendik M. Periodontal pathogens in the etiology of pancreatic Cancer. Gastrointest Tumors. 2017;3(3–4):125–7.PubMed
20.
Gaiser RA, et al. Enrichment of oral microbiota in early cystic precursors to invasive pancreatic cancer. Gut. 2019.
21.
Sharif R, et al. Impact of toll-like receptor 4 on the severity of acute pancreatitis and pancreatitis-associated lung injury in mice. Gut. 2009;58(6):813–9.PubMedCrossRef
22.
Fraher MH, O'Toole PW, Quigley EM. Techniques used to characterize the gut microbiota: a guide for the clinician. Nat Rev Gastroenterol Hepatol. 2012;9(6):312–22.PubMedCrossRef
23.
Mei QX, et al. Characterization of the duodenal bacterial microbiota in patients with pancreatic head cancer vs. healthy controls. Pancreatology. 2018;18(4):438–45.PubMedCrossRef
24.
Schulte A, et al. Association between helicobacter pylori and pancreatic cancer risk: a meta-analysis. Cancer Causes Control. 2015;26(7):1027–35.PubMedCrossRef
25.
Maisonneuve P, Lowenfels AB. Risk factors for pancreatic cancer: a summary review of meta-analytical studies. Int J Epidemiol. 2015;44(1):186–98.PubMedCrossRef
26.
Guo Y, Liu W, Wu J. Helicobacter pylori infection and pancreatic cancer risk: A meta-analysis. J Cancer Res Ther. 2016;12(Supplement):C229–c232.PubMed
27.
Yan AW, Schnabl B. Bacterial translocation and changes in the intestinal microbiome associated with alcoholic liver disease. World J Hepatol. 2012;4(4):110–8.PubMedPubMedCentralCrossRef
28.
Ding SZ, Goldberg JB, Hatakeyama M. Helicobacter pylori infection, oncogenic pathways and epigenetic mechanisms in gastric carcinogenesis. Future Oncol. 2010;6(5):851–62.PubMedCrossRef
29.
de Martel C, et al. Helicobacter pylori infection and development of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2008;17(5):1188–94.CrossRef
30.
31.
Del Castillo E, et al. The microbiomes of pancreatic and duodenum tissue overlap and are highly subject specific but differ between pancreatic Cancer and noncancer subjects. Cancer Epidemiol Biomark Prev. 2019;28(2):370–83.CrossRef
32.
Garcia-Castillo V, et al. Microbiota dysbiosis: a new piece in the understanding of the carcinogenesis puzzle. J Med Microbiol. 2016;65(12):1347–62.PubMedCrossRef
33.
Maisonneuve P, Amar S, Lowenfels AB. Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis. Ann Oncol. 2017;28(5):985–95.PubMed
34.
35.
Michaud DS, et al. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut. 2013;62(12):1764–70.PubMedCrossRef
36.
Lu H, et al. Tongue coating microbiome data distinguish patients with pancreatic head cancer from healthy controls. J Oral Microbiol. 2019;11(1):1563409.PubMedPubMedCentralCrossRef
37.
38.
39.
Raderer M, et al. Association between helicobacter pylori infection and pancreatic cancer. Oncology. 1998;55(1):16–9.PubMedCrossRef
40.
Stolzenberg-Solomon RZ, et al. Helicobacter pylori seropositivity as a risk factor for pancreatic cancer. J Natl Cancer Inst. 2001;93(12):937–41.PubMedCrossRef
41.
Risch HA, et al. ABO blood group, helicobacter pylori seropositivity, and risk of pancreatic cancer: a case-control study. J Natl Cancer Inst. 2010;102(7):502–5.PubMedPubMedCentralCrossRef
42.
Yu G, et al. Seropositivity to helicobacter pylori and risk of pancreatic cancer. Cancer Epidemiol Biomark Prev. 2013;22(12):2416–9.CrossRef
43.
Trikudanathan G, et al. Association between helicobacter pylori infection and pancreatic cancer. A cumulative meta-analysis. Jop. 2011;12(1):26–31.PubMed
44.
Xiao M, Wang Y, Gao Y. Association between helicobacter pylori infection and pancreatic cancer development: a meta-analysis. PLoS One. 2013;8(9):e75559.PubMedPubMedCentralCrossRef
45.
Yan AW, et al. Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology. 2011;53(1):96–105.PubMedCrossRef
46.
47.
Liu H, et al. Helicobacter pylori infection, atrophic gastritis, and pancreatic cancer risk: a meta-analysis of prospective epidemiologic studies. Medicine (Baltimore). 2017;96(33):e7811.CrossRef
48.
Kalaf EA, et al. Study of the cytoxin-associated gene a (CagA gene) in helicobacter pylori using gastric biopsies of Iraqi patients. Saudi J Gastroenterol. 2013;19(2):69–74.PubMedPubMedCentralCrossRef
49.
Chen S, et al. Helicobacter pylori cytotoxin-associated gene a protein upregulates alpha-enolase expression via Src/MEK/ERK pathway: implication for progression of gastric cancer. Int J Oncol. 2014;45(2):764–70.PubMedCrossRef
50.
Ertz-Archambault N, Keim P, Von Hoff D. Microbiome and pancreatic cancer: a comprehensive topic review of literature. World J Gastroenterol. 2017;23(10):1899–908.PubMedPubMedCentralCrossRef
51.
Risch HA, et al. Helicobacter pylori seropositivities and risk of pancreatic carcinoma. Cancer Epidemiol Biomark Prev. 2014;23(1):172–8.CrossRef
52.
Risch HA. Etiology of pancreatic cancer, with a hypothesis concerning the role of N-nitroso compounds and excess gastric acidity. J Natl Cancer Inst. 2003;95(13):948–60.PubMedCrossRef
53.
Blaser MJ. Hypotheses on the pathogenesis and natural history of helicobacter pylori-induced inflammation. Gastroenterology. 1992;102(2):720–7.PubMedCrossRef
54.
55.
Huang J, et al. A prospective cohort study on poor oral hygiene and pancreatic cancer risk. Int J Cancer. 2016;138(2):340–7.PubMedCrossRef
56.
57.
58.
Jin Y, et al. Identification and impact of hepatitis B virus DNA and antigens in pancreatic cancer tissues and adjacent non-cancerous tissues. Cancer Lett. 2013;335(2):447–54.PubMedCrossRef
59.
60.
Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park). 2002;16(2):217–26 229; discussion 230-2.
61.
Rubin DC, Shaker A, Levin MS. Chronic intestinal inflammation: inflammatory bowel disease and colitis-associated colon cancer. Front Immunol. 2012;3:107.PubMedPubMedCentralCrossRef
62.
63.
Dejea CM, et al. Patients with familial adenomatous polyposis harbor colonic biofilms containing tumorigenic bacteria. Science. 2018;359(6375):592–7.PubMedPubMedCentralCrossRef
64.
65.
Bartsch DK, Gress TM, Langer P. Familial pancreatic cancer--current knowledge. Nat Rev Gastroenterol Hepatol. 2012;9(8):445–53.PubMedCrossRef
66.
Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252–61.PubMedCrossRef
67.
Sadr-Azodi O, et al. Pancreatic Cancer following acute pancreatitis: a population-based matched cohort study. Am J Gastroenterol. 2018;113(11):1711–9.PubMedCrossRef
68.
Kirkegard J, et al. Acute pancreatitis and pancreatic Cancer risk: a Nationwide matched-cohort study in Denmark. Gastroenterology. 2018;154(6):1729–36.PubMedCrossRef
69.
Chung SD, et al. More than 9-times increased risk for pancreatic cancer among patients with acute pancreatitis in Chinese population. Pancreas. 2012;41(1):142–6.PubMedCrossRef
70.
71.
Redelman-Sidi G, et al. The canonical Wnt pathway drives macropinocytosis in Cancer. Cancer Res. 2018.
72.
Francis CL, et al. Ruffles induced by Salmonella and other stimuli direct macropinocytosis of bacteria. Nature. 1993;364(6438):639–42.PubMedCrossRef
73.
Redelman-Sidi G, et al. Oncogenic activation of Pak1-dependent pathway of macropinocytosis determines BCG entry into bladder cancer cells. Cancer Res. 2013;73(3):1156–67.PubMedPubMedCentralCrossRef
74.
Schmid SC, et al. Wntless promotes bladder cancer growth and acts synergistically as a molecular target in combination with cisplatin. Urol Oncol. 2017;35(9):544.e1–544.e10.CrossRef
75.
Terebiznik MR, et al. Elimination of host cell PtdIns(4,5)P(2) by bacterial SigD promotes membrane fission during invasion by Salmonella. Nat Cell Biol. 2002;4(10):766–73.PubMedCrossRef
76.
77.
78.
Mai CW, Kang YB, Pichika MR. Should a toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. Onco Targets Ther. 2013;6:1573–87.PubMedPubMedCentral
79.
Noureldein MH, Eid AA. Gut microbiota and mTOR signaling: insight on a new pathophysiological interaction. Microb Pathog. 2018;118:98–104.PubMedCrossRef
80.
Tanti JF, et al. Implication of inflammatory signaling pathways in obesity-induced insulin resistance. Front Endocrinol (Lausanne). 2012;3:181.
81.
82.
Kisfalvi K, et al. Insulin potentiates Ca2+ signaling and phosphatidylinositol 4,5-bisphosphate hydrolysis induced by Gq protein-coupled receptor agonists through an mTOR-dependent pathway. Endocrinology. 2007;148(7):3246–57.PubMedCrossRef
83.
Liauchonak I, et al. Int J Mol Sci. 2018;19(2).
84.
Panebianco C, et al. Engineered Resistant-Starch (ERS) Diet Shapes Colon Microbiota Profile in Parallel with the Retardation of Tumor Growth in In Vitro and In Vivo Pancreatic Cancer Models. Nutrients. 2017;9(4).PubMedCentralCrossRef
85.
Takayama S, et al. Effects of helicobacter pylori infection on human pancreatic cancer cell line. Hepatogastroenterology. 2007;54(80):2387–91.PubMed
86.
Pothuraju R, et al. Pancreatic cancer associated with obesity and diabetes: an alternative approach for its targeting. J Exp Clin Cancer Res. 2018;37(1):319.PubMedPubMedCentralCrossRef
87.
Beller M, et al. Lipid droplets: a dynamic organelle moves into focus. FEBS Lett. 2010;584(11):2176–82.PubMedCrossRef
88.
Gaida MM, et al. Expression of the bitter receptor T2R38 in pancreatic cancer: localization in lipid droplets and activation by a bacteria-derived quorum-sensing molecule. Oncotarget. 2016;7(11):12623–32.PubMedPubMedCentralCrossRef
89.
Kahle NA, et al. Bacterial quorum sensing molecule induces chemotaxis of human neutrophils via induction of p38 and leukocyte specific protein 1 (LSP1). Immunobiology. 2013;218(2):145–51.PubMedCrossRef
90.
Wu SV, et al. Expression of bitter taste receptors of the T2R family in the gastrointestinal tract and enteroendocrine STC-1 cells. Proc Natl Acad Sci U S A. 2002;99(4):2392–7.PubMedPubMedCentralCrossRef
91.
Huang H, et al. Oncogenic K-Ras requires activation for enhanced activity. Oncogene. 2014;33(4):532–5.PubMedCrossRef
92.
Daniluk J, et al. An NF-kappaB pathway-mediated positive feedback loop amplifies Ras activity to pathological levels in mice. J Clin Invest. 2012;122(4):1519–28.PubMedPubMedCentralCrossRef
93.
94.
95.
Sethi V, et al. The Role of the Microbiome in Immunologic Development and its Implication For Pancreatic Cancer Immunotherapy. Gastroenterol. 2019;156(7):2097–2115.e2.CrossRef
96.
97.
98.
Mao K, et al. Innate and adaptive lymphocytes sequentially shape the gut microbiota and lipid metabolism. Nature. 2018;554(7691):255–9.PubMedCrossRef
99.
100.
101.
Mazmanian SK, et al. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122(1):107–18.PubMedCrossRef
102.
Routy B, et al. Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors. Science. 2018;359(6371):91–7.CrossRefPubMed
103.
Gopalakrishnan V, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science. 2018;359(6371):97–103.CrossRefPubMed
104.
105.
Ma C, et al. Gut microbiome-mediated bile acid metabolism regulates liver cancer via NKT cells. Science. 2018;360(6391).
106.
Sethi V, et al. Gut microbiota promotes tumor growth in mice by modulating immune response. Gastroenterol. 2018.
107.
Thomas RM, et al. Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models. Carcinog. 2018.
108.
Clark CE, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007;67(19):9518–27.PubMedCrossRef
109.
Zheng L, et al. Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. Gastroenterol. 2013;144(6):1230–40.CrossRef
110.
Fukunaga A, et al. CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma. Pancreas. 2004;28(1):e26–31.PubMedCrossRef
111.
Ochi A, et al. MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells. J Exp Med. 2012;209(9):1671–87.PubMedPubMedCentralCrossRef
112.
De Monte L, et al. Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med. 2011;208(3):469–78.PubMedPubMedCentralCrossRef
113.
Hiraoka N, et al. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12(18):5423–34.PubMedCrossRef
114.
115.
116.
117.
Thomas S, et al. The host microbiome regulates and maintains human health: a primer and perspective for non-microbiologists. Cancer Res. 2017;77(8):1783–812.PubMedPubMedCentralCrossRef
118.
119.
Chakraborty S, et al. Current status of molecular markers for early detection of sporadic pancreatic cancer. Biochim Biophys Acta. 2011;1815(1):44–64.PubMed
120.
Momi N, et al. Interplay between smoking-induced genotoxicity and altered signaling in pancreatic carcinogenesis. Carcinogenesis. 2012;33(9):1617–28.PubMedPubMedCentralCrossRef
121.
122.
Michaud DS, et al. Physical activity, obesity, height, and the risk of pancreatic cancer. Jama. 2001;286(8):921–9.PubMedCrossRef
123.
124.
Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011;11(12):886–95.PubMedCrossRef
125.
Huang B, et al. Adiponectin promotes pancreatic cancer progression by inhibiting apoptosis via the activation of AMPK/Sirt1/PGC-1alpha signaling. Oncotarget. 2014;5(13):4732–45.PubMedPubMedCentralCrossRef
126.
Yang JP, et al. Association analysis of genetic variants of adiponectin gene and risk of pancreatic cancer. Int J Clin Exp Med. 2015;8(5):8094–100.PubMedPubMedCentral
127.
Bao Y, et al. A prospective study of plasma adiponectin and pancreatic cancer risk in five US cohorts. J Natl Cancer Inst. 2013;105(2):95–103.PubMedCrossRef
128.
Yoshimoto S, et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature. 2013;499(7456):97–101.PubMedCrossRef
129.
130.
Parekh PJ, Balart LA, Johnson DA. The influence of the gut microbiome on obesity. Metabolic Syndrome and Gastrointestinal Disease Clin Transl Gastroenterol. 2015;6:e91.PubMedCrossRef
131.
Thomas LV, Ockhuizen T, Suzuki K. Exploring the influence of the gut microbiota and probiotics on health: a symposium report. Br J Nutr. 2014;112(Suppl 1):S1–18.PubMedPubMedCentralCrossRef
132.
Pagliari D, et al. Gut microbiota-immune system crosstalk and pancreatic disorders. Mediat Inflamm. 2018;2018:7946431.CrossRef
133.
134.
135.
Devaraj S, Hemarajata P, Versalovic J. The human gut microbiome and body metabolism: implications for obesity and diabetes. Clin Chem. 2013;59(4):617–28.PubMedPubMedCentralCrossRef
136.
van Olden C, Groen AK, Nieuwdorp M. Role of intestinal microbiome in lipid and glucose metabolism in diabetes mellitus. Clin Ther. 2015;37(6):1172–7.PubMedCrossRef
137.
138.
139.
Fabryova H, Celec P. On the origin and diagnostic use of salivary RNA. Oral Dis. 2014;20(2):146–52.PubMedCrossRef
140.
Sturque, J., et al., Interest of studying the saliva metabolome, transcriptome and microbiome in screening for pancreatic cancer. J Stomatol Oral Maxillofac Surg, 2019.CrossRef
141.
Li X, et al. The expression and significance of feces cyclooxygensae-2 mRNA in colorectal cancer and colorectal adenomas. Saudi J Gastroenterol. 2017;23(1):28–33.PubMedPubMedCentralCrossRef
142.
Gourd E. TERT mutations in urine could predict bladder cancer recurrence. Lancet Oncol. 2017;18(8):e443.PubMedCrossRef
143.
144.
Geller LT, et al. Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine. Science. 2017;357(6356):1156–60.PubMedPubMedCentralCrossRef
145.
Nicholson JK, Holmes E, Wilson ID. Gut microorganisms, mammalian metabolism and personalized health care. Nat Rev Microbiol. 2005;3(5):431–8.PubMedCrossRef
146.
Li H, He J, Jia W. The influence of gut microbiota on drug metabolism and toxicity. Expert Opin Drug Metab Toxicol. 2016;12(1):31–40.PubMedCrossRef
147.
Choy ATF, et al. The microbiome of pancreatic cancer: from molecular diagnostics to new therapeutic approaches to overcome chemoresistance caused by metabolic inactivation of gemcitabine. Expert Rev Mol Diagn. 2018:1–5.
148.
Geller LT, Straussman R. Intratumoral bacteria may elicit chemoresistance by metabolizing anticancer agents. Mol Cell Oncol. 2018;5(1):e1405139.PubMedCrossRef
149.
Vande Voorde J, et al. Nucleoside-catabolizing enzymes in mycoplasma-infected tumor cell cultures compromise the cytostatic activity of the anticancer drug gemcitabine. J Biol Chem. 2014;289(19):13054–65.PubMedPubMedCentralCrossRef
150.
151.
Olarerin-George AO, Hogenesch JB. Assessing the prevalence of mycoplasma contamination in cell culture via a survey of NCBI's RNA-seq archive. Nucleic Acids Res. 2015;43(5):2535–42.PubMedPubMedCentralCrossRef
152.
153.
Paci A, et al. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics. Eur J Cancer. 2014;50(12):2010–9.PubMedCrossRef
154.
Zwielehner J, et al. Changes in human fecal microbiota due to chemotherapy analyzed by TaqMan-PCR, 454 sequencing and PCR-DGGE fingerprinting. PLoS One. 2011;6(12):e28654.PubMedPubMedCentralCrossRef
155.
Bien J, Palagani V, Bozko P. The intestinal microbiota dysbiosis and Clostridium difficile infection: is there a relationship with inflammatory bowel disease? Ther Adv Gastroenterol. 2013;6(1):53–68.CrossRef
156.
157.
Turnbaugh PJ, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122):1027–31.PubMedCrossRef
158.
159.
Ganesh BP, et al. Commensal Akkermansia muciniphila exacerbates gut inflammation in Salmonella Typhimurium-infected gnotobiotic mice. PLoS One. 2013;8(9):e74963.PubMedPubMedCentralCrossRef
160.
Montrose DC, et al. Celecoxib alters the intestinal microbiota and Metabolome in association with reducing polyp burden. Cancer Prev Res (Phila). 2016;9(9):721–31.CrossRef
161.
Forsgard RA, et al. Chemotherapy-induced gastrointestinal toxicity is associated with changes in serum and urine metabolome and fecal microbiota in male Sprague-Dawley rats. Cancer Chemother Pharmacol. 2017;80(2):317–32.PubMedPubMedCentralCrossRef
162.
Daliri EB, et al. The human microbiome and metabolomics: current concepts and applications. Crit Rev Food Sci Nutr. 2017;57(16):3565–76.PubMedCrossRef
163.
da Rocha Lapa F, et al. Anti-inflammatory effects of purine nucleosides, adenosine and inosine, in a mouse model of pleurisy: evidence for the role of adenosine A2 receptors. Purinergic Signal. 2012;8(4):693–704.PubMedPubMedCentralCrossRef
164.
Gomez G, Sitkovsky MV. Differential requirement for A2a and A3 adenosine receptors for the protective effect of inosine in vivo. Blood. 2003;102(13):4472–8.PubMedCrossRef
165.
Alexander JL, et al. Gut microbiota modulation of chemotherapy efficacy and toxicity. Nat Rev Gastroenterol Hepatol. 2017;14(6):356–65.PubMedCrossRef
166.
167.
168.
169.
170.
171.
Velicer CM, et al. Antibiotic use in relation to the risk of breast cancer. Jama. 2004;291(7):827–35.PubMedCrossRef
172.
Boursi B, et al. Recurrent antibiotic exposure may promote cancer formation--another step in understanding the role of the human microbiota? Eur J Cancer. 2015;51(17):2655–64.PubMedCrossRef
Metadata
Title
Role of the microbiome in occurrence, development and treatment of pancreatic cancer
Authors
Yicheng Wang
Gang Yang
Lei You
Jinshou Yang
Mengyu Feng
Jiangdong Qiu
Fangyu Zhao
Yueze Liu
Zhe Cao
Lianfang Zheng
Taiping Zhang
Yupei Zhao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Molecular Cancer / Issue 1/2019
Electronic ISSN: 1476-4598
DOI
https://doi.org/10.1186/s12943-019-1103-2

Other articles of this Issue 1/2019

Molecular Cancer 1/2019 Go to the issue

Correction

Correction to: A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1

Review

Crosstalk between autophagy and epithelial-mesenchymal transition and its application in cancer therapy

Review

Biogenesis, functions and clinical significance of circRNAs in gastric cancer

Review

Stem cells in homeostasis and cancer of the gut

Research

Circular RNA circSLC8A1 acts as a sponge of miR-130b/miR-494 in suppressing bladder cancer progression via regulating PTEN

Research

A novel protein encoded by a circular RNA circPPP1R12A promotes tumor pathogenesis and metastasis of colon cancer via Hippo-YAP signaling

2024 ASCO Annual Meeting Coverage

Highlights of the Day: Breast cancer – metastatic

Breast Cancer Video

In this session, Dr. Wolff provides his key takeaways from the data presented in the metastatic breast cancer oral abstract session at ASCO 2024.

Watch now

Highlights of the Day: Gynecologic cancer

Gynecologic Cancer Video

Highlights of the Day: Breast Cancer – local/regional/adjuvant

Breast Cancer Video

Neoadjuvant dual immunotherapy improves melanoma outcomes

04-06-2024 Melanoma News

» View more highlights on the ASCO 2024 congress hub page

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits